MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it is participating in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14 - 16, 2026 at the Lotte New York Palace Hotel in New York, where a pre-recorded fireside chat with Chief Executive Officer Dr. Jennifer Bath is available to registered attendees on demand.

“The question institutional investors are working through is where durable value sits in biological AI - and our answer is the representation layer, not any single model. A fireside format lets us make that case in the street’s terms and show what it means for the drug developers racing to put AI to work.”

The fireside chat was pre-recorded with Swayampakula Ramakanth, Ph.D., Managing Director, Senior Biotechnology Equity Research at H.C. Wainwright & Co. It is available on demand to registered conference attendees beginning Friday, September 11, 2026, at 7:00 a.m. ET via the conference platform.

Dr. Bath will also hold one-on-one meetings with investors during the conference. To request a meeting and to register for the conference: https://hcwevents.com/annualconference/

About MindWalk Holdings Corp.

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require, integrating AI, data, and advanced wet lab capabilities into one connected discovery ecosystem. At its core is HYFT Technology, a proprietary, function-aware representation of biology. Its HYFT fingerprints span sequence and structural biology and refined over 20 years of curation, form a continuously evolving biological representation of 660 million patterns and 25 billion relationships. This enriched biological representation is the architecture behind ReefIQ, the biological data substrate that provides context for life sciences, enriching data at ingestion and growing more valuable with each program run on it, and LensAI, the reasoning and application layer for target discovery, candidate diligence, portfolio decision support, and the agentic AI workflows pharma is racing to deploy. By design, value compounds in this HYFT representation layer, not in any individual AI model that runs on top of it.

Schreibe Deinen Kommentar